Neil Petry, MS

Associate Professor of Radiology
Department: Radiology
Division: Nuclear Medicine
Address: 0023, Sub-basement, Purple Zone
Duke Clinics, 200 Trent Drive
Durham, NC 27710
Office Phone: (919) 684-5636

Research Interests

As Director of the Duke Medical Center Radiopharmacy, which is permitted by the North Carolina Board of Pharmacy, I am responsible for the procurement, formulation, quality control testing, and dispensing of all radiopharmaceuticals for diagnostic, therapeutic, and research purposes for use in patients in Duke Hospital. Service accomplishments in fiscal year 2011-2012 included providing all radiopharmaceuticals used for routine patient care at Duke Medical Center. In addition, the Radiopharmacy service participated in a wide variety of clinical research protocols undertaken by Duke investigators either by consultation regarding pharmaceutical formulation of research compounds or actually performing these formulations as a specialized service. The major accomplishment over the last several years was to move the Radiopharmacy operation into a new state of the art USP <797> compliant clean room environment. This new lab space is specifically designed to satisfy a wide variety of sterile radiopharmaceutical compounding needs for both routine patient care and clinical research well into the future. My general research interests focus on the development and clinical evaluation of diagnostic and therapeutic radiopharmaceuticals for patient care. Specific research interests focus on the clinical applications of 1.) Carbon C-11, Nitrogen N-13, Oxygen 0-15 and Fluorine F-18 labeled radiopharmaceuticals for Positron Emission Tomography (PET) based molecular imaging and 2.) Radiolabeling antibodies, small molecules and peptides with Gallium Ga-68 for diagnosis and therapeutic radionuclides for treatment of human cancers. Finally, I am interested in the development of radiopharmaceutical care models in nuclear medicine to optimize the patient's health related quality of life, and achieve positive clinical outcomes, within realistic economic expenditures.


Schwarz, S; Norenberg, J; Berridge, M; Dragotakes, S; Hung, J; Link, J; Mason, NS; Mattmuller, S; Nickel, RA; Packard, A; al, E. The future of USP monographs for PET drugs. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2013;54:472-475.

Barrett, JA; Coleman, RE; Goldsmith, SJ; Vallabhajosula, S; Petry, NA; Cho, S; Armor, T; Stubbs, JB; Maresca, KP; Stabin, MG; Joyal, JL; Eckelman, WC; Babich, JW. First-in-Man Evaluation of 2 High-Affinity PSMA-Avid Small Molecules for Imaging Prostate Cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2013;54:380-387. Abstract

Cooper, JF; Petry, NA; Engelbrecht, H; Breslow, K. Alumina depyrogenates F 18 fludeoxyglucose injection during purification processes. PDA journal of pharmaceutical science and technology / PDA. 2012;66:214-220. Abstract

Sampson, JH; Brady, M; Raghavan, R; Mehta, AI; Friedman, AH; Reardon, DA; Petry, NA; Barboriak, DP; Wong, TZ; Zalutsky, MR; Lally-Goss, D; Bigner, DD. Colocalization of gadolinium-diethylene triamine pentaacetic acid with high-molecular-weight molecules after intracerebral convection-enhanced delivery in humans. Neurosurgery. 2011;69:668-676. Abstract

Norenberg, JP; Petry, NA; Schwarz, S. Operation of a radiopharmacy for a clinical trial. Seminars in Nuclear Medicine. 2010;40:347-356. Abstract

Barrett, JA; LaFrance, ND; Coleman, R; Goldsmith, SJ; Stubbs, JB; Petry, NA; Vallabhajosula, S; Maresca, K; Femia, F; Stabin, MG; Babich, JW. Targeting Metastatic Prostate Cancer (PCa) Using I-123-MIP-1072 & I-123-MIP-1095: A Phase I Clinical Study in Patients. European Journal of Nuclear Medicine and Molecular Imaging. 2009;36:S243-S243.

Sampson, JH; Akabani, G; Archer, GE; Berger, MS; Coleman, RE; Friedman, AH; Friedman, HS; Greer, K; Herndon, JE; Kunwar, S; McLendon, RE; Paolino, A; Petry, NA; Provenzale, JM; Reardon, DA; Wong, TZ; Zalutsky, MR; Pastan, I; Bigner, DD. Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro-Oncology. 2008;10:320-329. Abstract

Schultz, MK; Cessna, JT; Anderson, TL; Ponto, JA; Petry, N; Kowalsky, RJ; Palmer, MR; Beinlich, UF; Baker, W; Hinkle, GH; al, E. A performance evaluation of 90Y dose-calibrator measurements in nuclear pharmacies and clinics in the United States. Applied Radiation and Isotopes. 2008;66:252-260.

Wong, TZ; Lacy, JL; Petry, NA; Hawk, TC; Sporn, TA; Dewhirst, MW; Vlahovic, G. PET of hypoxia and perfusion with 62Cu-ATSM and 62Cu-PTSM using a 62Zn/62Cu generator. AJR. American journal of roentgenology. 2008;190:427-432. Abstract

Sampson, JH; Brady, ML; Petry, NA; Croteau, D; Friedman, AH; Friedman, HS; Wong, T; Bigner, DD; Pastan, I; Puri, RK; Pedain, C. Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning. Neurosurgery. 2007;60:ONS89-ONS98. Abstract

Chin, BB; Metzler, SD; Lemaire, A; Curcio, A; Vemulapalli, S; Greer, KL; Petry, NA; Turkington, TG; Coleman, RE; Rockman, H; Jaszczak, RJ. Left ventricular functional assessment in mice: feasibility of high spatial and temporal resolution ECG-gated blood pool SPECT. Radiology. 2007;245:440-448. Abstract

Hung, JC; Augustine, SC; Cheng, KT; Green, RL; Hopkins, WM; Laven, DL; Nelson, BR; Petry, NA; Ponto, JA; Quinton, TM; Swanson, DP. Explanations and unresolved issues pertaining to the development of the Nuclear Pharmacy Compounding Guidelines. Journal of the American Pharmacists Association. 2002;42:789-798. Abstract

Kaminski, MS; Zasadny, KR; Francis, IR; Milik, AW; Ross, CW; Moon, SD; Crawford, SM; Burgess, JM; Petry, NA; Butchko, GM. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. The New England journal of medicine. 1993;329:459-465. Abstract